Latest Shareholder Approval News

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Mantle Minerals has received conversion notices for over half of its outstanding convertible notes, prompting a shareholder vote in September to decide on converting $742,000 of debt into shares with attached options.

Mindax Limited has secured an option to acquire Norton Goldfields’ 35% stake in the Mt Forrest magnetite project, potentially gaining full ownership of a major iron ore asset in Western Australia’s Mid-West region.

Ramelius Resources has officially withdrawn its conditional takeover bid for Spartan Resources following court approval of a competing scheme of arrangement, setting the stage for Spartan’s shares to be acquired under the scheme.

Agrimin Limited progresses its Mackay Potash Project with ongoing strategic review and strong stakeholder backing, while securing $2.5 million through equity placement and completing the Tali Resources IPO.

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Lake Resources has raised $2.1 million through its At-the-Market facility by issuing 65 million shares to Acuity Capital, while extending the agreement to 2031 to support its Kachi Project and working capital needs.

IperionX has secured A$70 million through a share placement to fast-track expansion of its titanium production capacity in the U.S., aligning closely with Department of Defense priorities.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.